European Primary Care Cardiovascular Society

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Dietary education in the grocery store: a novel form of CV research

3' education - Apr. 19, 2022 - Prof. Eileen Handberg, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Clinical events with low-sodium diet in HF

3' education - Apr. 12, 2022 - Prof. Justin Ezekowitz

Adverse pregnancy outcomes reduced with treatment of chronic hypertension

3' education - Apr. 3, 2022 - Prof. Alan Tita, MD, PhD

Are HF patients harmed when they add salt to their egg?

3' education - Apr. 3, 2022 - Joseph Cleveland, MD

Enablement of RAASi therapy in HF using novel potassium binders

10' education - Mar. 8, 2022 - Prof. Javed Butler, MD and prof. Giuseppe Rosano, MD, PhD

Iron deficiency in HF: Outcomes, pathophysiology and management

10' education - Mar. 7, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD

Colchicine in coronary disease: From studies to clinical practice

5' education - Mar. 1, 2022 - Aernoud Fiolet, MD, PhD

Evaluating the role of a non-steroidal MRA in patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Global disparities in diagnosis and treatment of homozygous FH

5' education - Feb. 7, 2022 - Tycho Tromp, MD

A non-steroidal MRA in T2DM and CKD: Interpreting findings of studies

10' education - Feb. 1, 2022 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD - Online CME

The 2021 Polish guidelines on diagnosis and therapy of lipid disorders

5' education - Dec. 7, 2021 - Prof. Maciej Banach, MD, PhD

An algorithm-based program for cardiovascular healthcare

3' education - Nov. 22, 2021 - Alexander J. Blood, MD

Does low-dose aspirin lower risk of dementia in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

Assessing the effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD

Effects of coffee consumption on acute physiological changes: A randomized trial

3' education - Nov. 14, 2021 - Prof. Gregory Marcus, MD

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

No more benefit with time-restricted diet than calorie restriction alone

Literature - May 18, 2022 - Liu D et al. - N Engl J Med. 2022

Despite its increasing popularity, time-restricted eating did not show more benefits in Chinese obese patients after one year than restricting calories alone.

Bempedoic acid use results in long-term and safe LDL-c reduction

Literature - May 9, 2022 - Ballantyne CM, et al. - Am J Cardiol. 2022

In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.

Phase III trial with SGLT2i in HFpEF meets primary endpoint

News - May 9, 2022

A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in  patients who are already being treated with statins.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.

Extended treatment of DOAC results in less hospitalizations for recurrent VTE

Literature - May 4, 2022 - Pawar A, et al. - JAMA. 2022

An exploratory analysis showed that apixaban as extended treatment (>90 days) after hospitalization for venous thromboembolism (VTE) is associated with a lower rate of hospitalizations for recurrent VTE versus warfarin as extended treatment.

Lp(a) levels increased with age.

Literature - May 2, 2022 - De Boer LM, et al. - Atherosclerosis. 2022

Lp(a) levels are thought to stay stable over time, at least in adults. As several lipid values change during childhood, Lp(a) values were measured in a large cohort of children. The result: Lp(a) levels increased with age.

Risk factors in childhood associated with cardiovascular events in adulthood

Literature - Apr. 26, 2022 - Jacobs, Jr. DE et al. - N Engl J Med. 2022

This study demonstrated that traditional CV factors (BMI, SBP, total cholesterol level, triglyceride level, and smoking) in childhood are associated with CV events during adulthood.

Sleep restriction causes increases in body weight and abdominal fat

Literature - Apr. 25, 2022 - Covassin N et al. - J Am Coll Cardiol. 2022

A randomized, controlled, crossover study showed that sleep restriction leads to excess calorie intake, weight gain and an increase in abdominal fat.

Dietary education in the grocery store: a novel form of CV research

3' education - Apr. 19, 2022 - Prof. Eileen Handberg, PhD
Prof. Handberg shares and interprets the findings from the SuperWIN study.

ACC 2022 Prof. Handberg shares and interprets the findings from the SuperWIN study. "We have the ability with this type of intervention to really impact multiple generations", she said.

Safely lowering of LDL-c with bempedoic acid in subgroups of patients

News - Apr. 19, 2022

ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.

Improved guideline-directed therapy prescription for HFrEF with electronic health record alert

News - Apr. 19, 2022

ACC 2022 This randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.